ARTICLE
25 February 2013

Tiny Particles With Big Benefits

SJ
Steptoe LLP
Contributor
In more than 100 years of practice, Steptoe has earned an international reputation for vigorous representation of clients before governmental agencies, successful advocacy in litigation and arbitration, and creative and practical advice in structuring business transactions. Steptoe has more than 500 lawyers and professional staff across the US, Europe and Asia.
The use of nanomaterials and nanotechnology in general is at the forefront of innovation with the potential to transform industry and everyday life in many sectors to benefit consumers, workers, patients, and indeed all of society.
European Union Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Nanotechnology and Nanomaterials

The use of nanomaterials and nanotechnology in general is at the forefront of innovation with the potential to transform industry and everyday life in many sectors to benefit consumers, workers, patients, and indeed all of society.

To keep you informed of the latest developments and challenges, Steptoe is pleased to announce that Dr. Anna Gergely, Director of Environment, Health and Safety at Steptoe's Brussels office and head of the firm's nanotechnology practice, was asked by AmCham EU to lead the effort to publish their brochure on nanotechnology and nanomaterials titled "Tiny Particles with Big Benefits." Dr. Gergely, who chairs the AmCham EU Nanotechnologies Working Group, contributed to the EU Regulation chapter of the publication. 

"The use of nanomaterials and nanotechnology in general is at the forefront of innovation with the potential to transform industry and everyday life in many sectors to benefit consumers, workers, patients, and indeed all of society," say the authors.

As a key enabling technology, nanotechnology has the potential to boost the competitiveness of EU industry, but the evolving regulatory framework will be instrumental in determining whether EU firms become and/or remain innovation leaders. To make this happen, Europe must create a suitable regulatory environment which supports nanotechnology development and innovation.

Read the entire publication here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
25 February 2013

Tiny Particles With Big Benefits

European Union Food, Drugs, Healthcare, Life Sciences
Contributor
In more than 100 years of practice, Steptoe has earned an international reputation for vigorous representation of clients before governmental agencies, successful advocacy in litigation and arbitration, and creative and practical advice in structuring business transactions. Steptoe has more than 500 lawyers and professional staff across the US, Europe and Asia.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More